Multicenter Study on the Role of Neurodegeneration Biomarkers in Obstructive Sleep Apnea Syndrome With Residual Excessive Daytime Sleepiness. — EDS in OSA

Sleep Apnea Syndromes Clinical Trial

Official title:
Multicenter Study on the Role of Neurodegeneration Biomarkers in Characterizing the Severity of Disease and Response to Therapeutic Treatment of Patients With Obstructive Sleep Apnea Syndrome With Residual Excessive Daytime Sleepiness.

Status Recruiting

Clinical Trial Summary

Excessive daytime sleepiness which still remains after an effective treatment with nocturnal ventilotherapy or with other specific treatments (positional therapy, oro-mandibular devices) in patients with obstructive sleep apnea syndrome has a prevalence of 55% of treated cases, representing a notable theme of clinical and research interest. In recent years there have been several studies on the use of wakefulness-promoting drugs generally prescribed in patients with narcolepsy, in this disorder with promising results. Right in consideration of the forthcoming approval of these drugs, it is important to find biomarkers able to predict which patients will develop daytime sleepiness resistant to ventilatory treatment. Several studies have highlighted the association between obstructive sleep apnea syndrome and the increase of cerebral amyloid beta deposits, concluding that apnoic disorder can be considered a risk factor for the development of cognitive impairment and Alzheimer';s disease. In this scenario, it would be useful to identify biological markers able to underline which clinical phenotypes of sleep apnea syndrome are more associated with residual excessive daytime sleepiness and/or cognitive impairment. In recent years several kits for the assay of biomarkers of neurodegeneration have been developed not only in CSF, but also in human serum. Among them, the most important are light chain neurofilaments (NFL), amyloid isoforms 40 and 42 (Ab40 and Ab42). Other biomarkers found in neurodegenerative diseases associated with excessive daytime sleepiness are orexin A (OXA) and histamine (HA). In this view, the aim of this study is to evaluate the role of biomarkers of neurodegeneration in characterizing disease severity and response to treatment of obstructive sleep apnea syndrome with residual excessive daytime sleepiness.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05795270
Study type	Observational
Source	Istituto Auxologico Italiano
Contact	Riccardo Cremascoli, MD
Phone	+393497292068
Email	r.cremascoli@auxologico.it
Status	Recruiting
Phase
Start date	December 15, 2020
Completion date	August 24, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05477719` - Effect of Compression Stockings on the Number of Apneas/Hypopneas Per Hour of Sleep in Patients With Syndrome Obstructive Sleep Apnea/Hypopnea as Compared to no Treatment	N/A
Completed	`NCT04979234` - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome	N/A
Terminated	`NCT02735694` - Cycloserine in the Treatment of Sleep Apnea	Phase 1
Active, not recruiting	`NCT02470182` - Screening for Sleep Disordered Breathing With Minimally Obtrusive Sensors
Completed	`NCT02088723` - Testing the Elevation as Sleep Apnea Treatment	N/A
Completed	`NCT01457014` - Sleep Disordered Breathing and Chronic Pain	N/A
Completed	`NCT00976417` - Mechanisms of Action of Adaptive Servoventilation	N/A
Completed	`NCT00860743` - Respiratory and Autonomic Plasticity Following Intermittent Hypoxia	Early Phase 1
Active, not recruiting	`NCT00371293` - The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease	N/A
Completed	`NCT00607893` - Efficacy of Continuous Positive Airway Pressure in Reducing Oxidative Stress in Individuals With Sleep Apnea	N/A
Completed	`NCT00083798` - Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland	N/A
Completed	`NCT00070681` - Outcomes of Sleep Disorders in Older Men	Phase 3
Completed	`NCT00089752` - Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea	N/A
Completed	`NCT00051363` - Apnea Positive Pressure Long-Term Efficacy Study	Phase 3
Completed	`NCT00046670` - Sleep Disordered Breathing, APOE, and Lipid Metabolism	N/A
Completed	`NCT00031239` - Sleep Apnea in Look AHEAD Participants - Ancillary to Look AHEAD	N/A
Terminated	`NCT00006321` - Neurocognitive Function in Snoring Children	N/A
Completed	`NCT00006323` - Neurobehavioral Consequences of Sleep Apnea in Children	N/A
Completed	`NCT00005511` - SCOR in Neurobiology of Sleep--Intermediate Traits for Sleep Apnea	N/A
Completed	`NCT00005275` - Sleep Heart Health Study (SHHS) Data Coordinating Center	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.